Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun 1;322(6):F639-F654.
doi: 10.1152/ajprenal.00398.2021. Epub 2022 Apr 4.

Comparison of the surgical resection and infarct 5/6 nephrectomy rat models of chronic kidney disease

Affiliations
Review

Comparison of the surgical resection and infarct 5/6 nephrectomy rat models of chronic kidney disease

Ryan J Adam et al. Am J Physiol Renal Physiol. .

Abstract

The 5/6 nephrectomy rat remnant kidney model is commonly used to study chronic kidney disease (CKD). This model requires the removal of one whole kidney and two-thirds of the other kidney. The two most common ways of producing the remnant kidney are surgical resection of poles, known as the polectomy model, or ligation of superior and inferior segmental renal arteries, resulting in pole infarction. These models have much in common, but also major phenotypic differences, and thus respectively model unique aspects of human CKD. The purpose of this review is to summarize phenotypic similarities and differences between these two models and their relation to human CKD while emphasizing their vascular phenotype. In this article, we review studies that have evaluated arterial blood pressure, the renin-angiotensin-aldosterone-system, autoregulation, nitric oxide, single-nephron physiology, angiogenic and antiangiogenic factors, and capillary rarefaction in these two models. In terms of phenotypic similarities, both models spontaneously develop hallmarks of human CKD including uremia, fibrosis, capillary rarefaction, and progressive renal function decline. They both undergo whole organ hypertrophy, hyperfiltration of functional nephrons, reduced renal expression of vascular endothelial growth factor, increased renal expression of antiangiogenic thrombospondin-1, impaired renal autoregulation, and abnormal vascular nitric oxide physiology. In terms of key phenotypic differences, the infarction model develops rapid-onset, moderate to severe systemic hypertension and the polectomy model develops early normotension followed by mild to moderate hypertension. Rats subjected to the infarction model have a markedly more active renin-angiotensin-aldosterone system. Comparison of these two models facilitates understanding of how they can be used for studying CKD pathophysiology.

Keywords: 5/6 nephrectomy; autoregulation; blood pressure; chronic kidney disease; renin-angiotensin-aldosterone system.

PubMed Disclaimer

Conflict of interest statement

No conflicts of interest, financial or otherwise, are declared by the authors.

Figures

None
Graphical abstract
Figure 1.
Figure 1.
Schematic summary of 5/6 nephrectomy (5/6Nx) by surgical resection (A), 5/6Nx by infarction (B), and sham-operated nephrectomy (C). All three procedures include kidney access by laparotomy. D: although the mechanism of primary renal insult is variable in human chronic kidney disease and different from both the infarction and polectomy 5/6Nx models, progressive decline of renal function is common to all. R, right.
Figure 2.
Figure 2.
Tissue renin content in the infarction rat scar (infarcted poles) regions is highly elevated relative to nonscar tissue and is increased relative to the polectomy rat tissue edge and nonedge renin content. Graphical data were recreated from tabular data (Table 2) from Ibrahim et al. (15).

Similar articles

Cited by

References

    1. Kim K, Anderson EM, Thome T, Lu G, Salyers ZR, Cort TA, O’Malley KA, Scali ST, Ryan TE. Skeletal myopathy in CKD: a comparison of adenine-induced nephropathy and 5/6 nephrectomy models in mice. Am J Physiol Renal Physiol 321: F106–F119, 2021. doi:10.1152/ajprenal.00117.2021. - DOI - PMC - PubMed
    1. Mannon EC, O'Connor PM. Alkali supplementation as a therapeutic in chronic kidney disease: what mediates protection? Am J Physiol Renal Physiol 319: F1090–F1104, 2020. doi:10.1152/ajprenal.00343.2020. - DOI - PMC - PubMed
    1. Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet 389: 1238–1252, 2017. doi:10.1016/S0140-6736(16)32064-5. - DOI - PubMed
    1. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS. Prevalence of chronic kidney disease in the United States. JAMA 298: 2038–2047, 2007. doi:10.1001/jama.298.17.2038. - DOI - PubMed
    1. Chuppa S, Liang M, Liu P, Liu Y, Casati MC, Cowley AW, Patullo L, Kriegel AJ. MicroRNA-21 regulates peroxisome proliferator-activated receptor α, a molecular mechanism of cardiac pathology in cardiorenal syndrome type 4. Kidney Int 93: 375–389, 2018. doi:10.1016/j.kint.2017.05.014. - DOI - PMC - PubMed

Substances